Form 4: Enanta Pharmaceuticals CEO Jay R. Luly Reports Acquisition and Disposal of Common Stock

Jay R. Luly, President and CEO of Enanta Pharmaceuticals, reports the acquisition of 25,500 shares of common stock and disposal of 7,484 shares to cover withholding taxes.

Summary

• On February 12, 2025, Jay R. Luly, the President and CEO of Enanta Pharmaceuticals, acquired 25,500 shares of Enanta common stock.
• These shares were issued under performance share units (PSUs) that vested based on the achievement of two-year research and development milestones in the 2023-2024 period.
• The Compensation Committee of Enanta's Board of Directors determined the vesting of these PSUs.
• Simultaneously, Luly disposed of 7,484 shares of common stock to cover withholding taxes due as a result of the PSU settlement at a price of $5.59.
• Following these transactions, Luly beneficially owns 864,654 shares of Enanta common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares through PSU vesting suggests the company met certain R&D milestones, which is a positive indicator. The disposal of shares for tax purposes is a routine transaction.

Positives

• The vesting of performance share units indicates the achievement of research and development milestones, which is a positive sign for the company's progress.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Similar filings are common across publicly traded pharmaceutical companies like Gilead Sciences, Vertex Pharmaceuticals, and AbbVie, where executives often receive stock-based compensation.
• The vesting of PSUs based on R&D milestones is a typical incentive structure used to align management's interests with the company's long-term research and development goals, similar to programs at companies like Amgen and Regeneron.

Stakeholder Impact

• The vesting of PSUs and subsequent increase in shares held by the CEO could be viewed positively by shareholders, as it aligns management's interests with the company's performance.

Key Dates